Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • Rights and Permissions
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • Rights and Permissions
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-β Does Not Result in an In Vivo Response Directed at the Subdominant Epitope

V. Peter Yeung, Judy Chang, Jeff Miller, Christopher Barnett, Marcia Stickler and Fiona A. Harding
J Immunol June 1, 2004, 172 (11) 6658-6665; DOI: https://doi.org/10.4049/jimmunol.172.11.6658
V. Peter Yeung
Genencor International, Palo Alto, CA 94304
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judy Chang
Genencor International, Palo Alto, CA 94304
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeff Miller
Genencor International, Palo Alto, CA 94304
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Barnett
Genencor International, Palo Alto, CA 94304
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcia Stickler
Genencor International, Palo Alto, CA 94304
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fiona A. Harding
Genencor International, Palo Alto, CA 94304
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Proliferative responses to human IFN-β peptides by BALB/cByJ mice. Three mice were immunized with 25 μg of human IFN-β i.p. in alum on days 1, 3, and 10. Splenocytes were tested for proliferation to 5 μg/ml peptides in vitro on day 15. All 52 peptides describing the sequence of human IFN-β were tested in triplicate. The peptide numbers are listed on the x-axis. The first amino acid in each peptide can be calculated using the following formula: ((3n) − 2), where n is the peptide number listed. SIs were calculated for each peptide. The three mice were tested independently. The average SI for the three mice ± SD is shown on the y-axis. Average background proliferation ranged from 4100 to 6450 cpm.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Proliferative response to IFN 118–132 amino acid variants. Three BALB/cByJ mice were immunized with 25 μg of human IFN-β i.p. in alum on days 1, 3 and 10. Splenocytes were tested for proliferation in response to peptides in vitro on day 15. The sequence of the 118–132 peptide, SSLHLKRYYGRILHY, was modified by substituting an alanine at each position, except the lysine at position 130. Each peptide was tested in triplicate. The three mice were tested independently, and SIs were calculated. The average SI for the three mice ± SD is shown on the y-axis. Average background cpm ranged from 3984 to 4513.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Immunization with the variant IFN-β molecule results in reduced T cell responses to both IFN-β T cell epitope regions. BALB/cByJ mice were immunized with 25 μg of either human IFN-β (A and B) or the I129V IFN-β variant (C and D) i.p. in alum on days 1, 3, and 10. Proliferation in vitro was tested on day 15. Results are shown as average cpm from duplicate wells (A and C) or as SIs (B and D). Average background cpm were 1499 for the I129V-immunized mouse splenocytes and 1517 for the IFN-β-immunized mouse splenocytes.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Proliferative responses to IFN-β and the I129V IFN-β variant. Groups of four BALB/cByJ mice were immunized with human IFN-β (A, C, E, and G) or the I129V IFN-β variant (B, D, F, and H) on days 1, 3, 10, 17, 21, and 26. On day 31 pooled splenocytes were tested for proliferative responses in vitro to human IFN-β (♦) or I129V IFN-β variant (□). Mice were immunized i.p. using alum as an adjuvant. Mice received 5 μg (A and B), 10 μg (C and D), 25 μg (E and F) or 50 μg (G and H) per immunization.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Ab responses to the I129V IFN-β variant do not increase either over time or with an increasing dose of protein. Four BALB/cByJ mice per group were immunized i.p. with 5, 10, 25, or 50 μg of human IFN-β (♦) or the I129V IFN-β variant (□) in alum on days 1, 3, 10, 17, and 21. Serum samples were obtained and tested by ELISA for IFN-β-specific IgG1 on day 15 (A), day 21 (B), and day 26 (C). A time course is presented in D for the 50-μg dose.

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    The I129V mutation does not disrupt Ab-binding epitopes in IFN-β and does not create a new specificity. BALB/c mice were immunized with 50 μg of either IFN-β (♦ and ⋄) or the I129V-modified variant (• and ○) i.p. in alum on days 1, 3, and 10. Serum samples were taken on d = 15. ELISA plates were coated with 2 μg/ml of either IFN-β (♦ and •) or the I129V-modified variant (⋄ and ○), and the assay was performed as described in Materials and Methods.

PreviousNext
Back to top

In this issue

The Journal of Immunology: 172 (11)
The Journal of Immunology
Vol. 172, Issue 11
1 Jun 2004
  • Table of Contents
  • About the Cover
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-β Does Not Result in an In Vivo Response Directed at the Subdominant Epitope
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
Citation Tools
Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-β Does Not Result in an In Vivo Response Directed at the Subdominant Epitope
V. Peter Yeung, Judy Chang, Jeff Miller, Christopher Barnett, Marcia Stickler, Fiona A. Harding
The Journal of Immunology June 1, 2004, 172 (11) 6658-6665; DOI: 10.4049/jimmunol.172.11.6658

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-β Does Not Result in an In Vivo Response Directed at the Subdominant Epitope
V. Peter Yeung, Judy Chang, Jeff Miller, Christopher Barnett, Marcia Stickler, Fiona A. Harding
The Journal of Immunology June 1, 2004, 172 (11) 6658-6665; DOI: 10.4049/jimmunol.172.11.6658
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Innate Immunity Together with Duration of Antigen Persistence Regulate Effector T Cell Induction
  • Regulatory Roles of IL-2 and IL-4 in H4/Inducible Costimulator Expression on Activated CD4+ T Cells During Th Cell Development
  • Induction of CD4+ T Cell Apoptosis as a Consequence of Impaired Cytoskeletal Rearrangement in UVB-Irradiated Dendritic Cells
Show more CELLULAR IMMUNOLOGY AND IMMUNE REGULATION

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • Public Access
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2019 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606